Table 1.
Clinical characteristics
| Controls (N=31) |
DLB (N=31) |
AD (N=31) |
Test statistic P value |
|
| Age (years±SD) | 66.0±8.6 | 73.9±7.6* | 74.1±7.4* |
10.729† <0.001 |
| Gender (male:female) | 14:17 | 20:11 | 18:13 | 2.443‡ 0.295 |
| Years of education (years±SD) | 12.7±2.5 | 12.7±3.2 | 13.3±3.8 | 0.170§ 0.919 |
| Disease duration (years±SD) | – | 3.8±1.7 | 4.5±2.4 | 310.0¶ 0.260 |
| MoCA (score ±SD) | 29±1 | 18±6* | 19±5* |
60.472§ <0.001 |
| FCSRT-IR sum total (score, LQ-UQ) | – | 46 39–48 |
42 19.5–47 |
344.5¶ 0.166 |
| FCSRT-IR free recall (score, LQ-UQ) | – | 18 7–24 |
14 5–20.5 |
363.5¶ 0.278 |
| CSDD (score, LQ-UQ) | – | 2 1–4 |
2 1–4 |
481.0¶ 0.994 |
| CAF (score, LQ-UQ) | – | 4** 2–8 |
0 0–0 |
117.5¶ <0.001 |
| UPDRS total (score, LQ-UQ) | – | 31** 18–45 |
7 4–11 |
71¶ <0.001 |
| UPDRS motor examination (score, LQ-UQ) | – | 14** 8–21 |
2 0–5 |
107.5¶ <0.001 |
| NPI total (score, LQ-UQ) | – | 8 6–20 |
6 3–11 |
343.5¶ 0.053 |
| Cholinesterase inhibitors (no of patients, %) | 0 | 30 (96.8%)¶** | 24 (77.4%)* |
66.769‡ <0.001 |
| Memantine hydrochloride (no of patients, %) | 0 | 2 (6.5%) | 4 (12.9%) | 4.276‡ 0.118 |
| Antipsychotic medications (no of patients, %) | 1 (3.2%) | 6 (19.3%)¶** | 1 (3.2%) |
6.838‡ 0.033 |
| Medications for Parkinsonism (no of patients, %) | 0 | 8 (25.8%)¶** | 0 |
17.506‡ <0.001 |
Results are presented as mean±SD or median with Lower Quartile (LQ) to Upper Quartile (UQ) below, or proportions of total number. Statistical tests are denoted with symbols.
*.ANOVA.
†χ2.
‡χ.Kruskal-Wallis.
§Mann-Whitney U.
¶Significantly different from controls (p<0.05).
**Significantly different from AD (p<0.05).
AD, Alzheimer’s disease; CAF, clinician assessment of fluctuation; CSDD, Cornell Scale for Depression in Dementia; DLB, dementia with Lewy bodies; FCSRT-IR, free and cued selective reminding test-immediate recall; MoCA, Montreal cognitive assessment; NPI, neuropsychiatric inventory; UPDRS, Unified Parkinson’s Disease Rating Scale.